Abstract
Peptide loading of MHC-I molecules plays a critical role in the T cell response to infections and tumors as well as to interactions with inhibitory receptors on natural killer (NK) cells. To facilitate and optimize peptide acquisition, vertebrates have evolved specialized chaperones to stabilize MHC-I molecules during their biosynthesis and to catalyze peptide exchange favoring high affinity or optimal peptides to permit transport to the cell surface where stable peptide/MHC-I (pMHC-I) complexes are displayed and are available for interaction with T cell receptors and any of a host of inhibitory and activating receptors. Although components of the endoplasmic reticulum (ER) resident peptide loading complex (PLC) were identified some 30 years ago, the detailed biophysical parameters that govern peptide selection, binding, and surface display have recently been understood better with advances in structural methods including X-ray crystallography, cryogenic electron microscopy (cryo-EM), and computational modeling. These approaches have provided refined mechanistic illustration of the molecular events involved in the folding of the MHC-I heavy chain, its coordinate glycosylation, assembly with its light chain, β2-microglobulin (β2m), its association with the PLC, and its binding of peptides. Our current view of this important cellular process as it relates to antigen presentation to CD8+ T cells is based on many different approaches: biochemical, genetic, structural, computational, cell biological, and immunological. In this review, taking advantage of recent X-ray and cryo-EM structural evidence and molecular dynamics simulations, examined in the context of past experiments, we attempt a dispassionate evaluation of the details of peptide loading in the MHC-I pathway. By critical evaluation of several decades of investigation, we outline aspects of the peptide loading process that are well-understood and indicate those that demand further detailed investigation. Further studies should contribute not only to basic understanding, but also to applications for immunization and therapy of tumors and infections.
1 Introduction
Survival amidst a host of infectious agents and the scourge of neoplasia requires multicellular organisms to recognize pathogens, pathogen-infected cells, and dysregulated cancer cells. The vertebrate immune system has evolved a complex and effective molecular and cellular system to accomplish this formidable task, and one group of effective solutions includes the means to discriminate cells that no longer function normally. Central to this recognition function are cell surface molecules encoded by the major histocompatibility complexes of higher vertebrates, known collectively as MHC molecules and functionally discerned as two heterodimeric classes, MHC-I and MHC-II. Classical MHC-I molecules, designated H2-K, -D, and -L in the mouse and HLA-A,-B, and -C in the human are expressed on the surface of virtually all nucleated cells, paired with a monomorphic chain, β2m (). The MHC-I heavy chains, ~ 46 kD in size, are most remarkable for their high degree of polymorphism (some 25,000 HLA class I and 10,000 HLA class II alleles are now recognized by the Immuno Polymorphism Database (IPD) (, )). Our focus for this review is the MHC-I molecules and the mechanism by which they are loaded with antigenic peptides. The collective process of generating, binding, exchanging, and displaying peptide/MHC (pMHC) complexes at the cell surface is designated “antigen processing and presentation,” which has been reviewed extensively elsewhere (–). The goal of this review is to offer perspective on recent experiments that address mechanistic details of peptide loading onto MHC-I. Figure 1 offers a timeline of some of the major experimental/structural insights concerning MHC-I peptide loading.
Figure 1
Our current understanding draws on extensive biochemical, genetic, and functional studies and focuses specifically on structural visualization from X-ray (–), small angle X-ray scattering (SAXS) () and cryo-EM (, ) methods. In addition, it draws on dynamic observations based on molecular dynamics simulations and nuclear magnetic resonance (NMR) spectroscopy (, –). We emphasize that the important functional unit in MHC-I peptide loading is the PLC, governed largely by the tapasin chaperone/editor. (Tapasin, also known as TAP binding protein (TAPBP), was originally identified in immunoprecipitation experiments showing that it bridged the transporter associated with antigen processing (TAP) to MHC-I ()). Major insight into tapasin function has been gained more recently by studies of a similar molecule, TAP binding protein, related (TAPBPR), in large part because it has been more amenable to experimental study and manipulation.
The PLC consists of the heterodimer peptide transporter TAP1/2, the protein disulfide isomerase endoplasmic reticulum (ER) protein 57 (ERp57) (also known as PDIA3), the lectin chaperone calreticulin, and tapasin (, ). The TAP1/2 heterodimer is an ATP-dependent peptide transporter that shuttles peptides of length 8 to 16 (even as large as 40) derived from cytoplasmic degradation of proteins by the proteasome into the ER (). TAP mutant mice are defective in MHC-I cell surface expression and antigen presentation, resulting in defective CD8+ T cell development (). Following transport by TAP, peptides are subject to amino-terminal trimming by ER aminopeptidase (ERAP) 1 () or ERAP 2 () in the human, or ER associated with antigen processing (ERAAP) in the mouse (). Cells or animals defective in the genes encoding tapasin (–) revealed a critical role for tapasin both in stabilizing unstable MHC-I molecules bound to low affinity peptides and in catalyzing peptide exchange in a process that selects for high affinity MHC-I peptides. Early biochemical and functional studies of tapasin and its covalent disulfide-mediated interaction with ERp57 () were substantiated by the determination of the three-dimensional structure of a molecular heterodimer of tapasin with ERp57 (). This not only established the structural basis of tapasin and the tapasin/ERp57 association with PLC function but defined some of the functional regions of tapasin by careful mutagenic studies. Concurrent molecular modeling and dynamics studies pointed to the concerted roles of tapasin, ERp57, and calreticulin in stabilizing MHC-I and facilitating peptide loading (, 38, 39). However, because of the lack of direct knowledge of the contacts of tapasin with the MHC molecule, a more complete understanding of the mechanisms involved in MHC-I chaperoning and catalysis of peptide exchange remained lacking.
Because a number of tapasin expression systems, though useful for examining tapasin interactions in vitro (40–43), proved unable to provide material suitable for high resolution structural studies of the interaction of tapasin with MHC-I, interest in tapasin and the PLC diverted to studies of the tapasin homologue, TAPBPR. The TAPBPR gene (on human chromosome 12p13.3) had been identified in a genetic region paralogous to the human MHC (at 6p21.3), and its encoded protein was some 20% identical to that of tapasin (). Because of the similarity of predicted structural domains and potential for equivalence in function, several laboratories pursued biochemical and functional (, ), and eventually structural studies of TAPBPR (, , , 44). These findings initiated renewed interest in the intricacies of MHC-I/chaperone interactions. Biochemical studies of TAPBPR established its catalytic role in peptide exchange, confirming the view that its mechanism would be similar to that of tapasin (, ).
More recently several major advances have orchestrated a return to understanding the details of tapasin/MHC-I interactions. These include the crystal structure determination of tapasin/MHC-I/ERp57 complex (), the crystal structure of a tapasin/MHC-I complex (), and the cryo-EM visualization of complete PLC preparations (, ). This review will aim to summarize some new findings based on studies with TAPBPR and unite their interpretation with structural studies of tapasin complexed with MHC-I as probed crystallographically, by cryo-EM, and computationally. Our approach will be primarily structural, focusing on the regions of TAPBPR and tapasin that have been identified to interact with MHC-I and other PLC components.
2 Tapasin and TAPBPR in chaperoning and peptide loading
2.1 Tapasin-identification of functional domains by mutagenesis and X-ray crystallography
As noted above, tapasin was first identified in studies of the TAP transporter as a molecule bridging MHC-I to TAP (, , 45–47). X-ray crystal structure determination of tapasin bound to the oxidoreductase ERp57 revolutionized our understanding of the functional domains of tapasin (). As shown in Figure 2, the 2.60 Å crystal structure of this complex revealed the surface of tapasin that interacts with ERp57, and, on the opposite face of the molecule, a large region available for interaction with MHC-I. The contacts of tapasin to ERp57 emphasized the stabilizing influence of ERp57 for tapasin. Further mutational analysis in this paper identified several regions of tapasin that affected complementation of cell surface expression of MHC-I (HLA-A, -B, and -C) in tapasin deficient cells (Figures 2B, C).
Figure 2
2.2 TAPBPR-a welcome and important diversion
Although tapasin function was well-studied with respect to MHC-I surface expression and peptide presentation, efforts to explore the structural mechanistic basis of peptide editing and MHC-I stabilization by tapasin languished until Boyle and colleagues diverted attention of the antigen presentation community to TAPBPR (). Because of its higher affinity for MHC-I and somewhat better behavior as a recombinant molecule, TAPBPR proved to be amenable for biochemical/binding studies as well as small angle X-ray scattering (SAXS) studies (, , 48). TAPBPR was shown to function as a catalyst in peptide exchange (, ) and to interact with MHC-I and UDP-glucose:glycoprotein glucosyltransferase 1 (UGT1) in a pathway that monitors the quality of MHC-I peptide loading (49). The SAXS studies confirmed the impression that tapasin and TAPBPR possess similar dimensions at low resolution, and binding studies indicated that TAPBPR had higher affinity for MHC-I molecules emptied of peptide by photolysis of photolabile peptides than for those bound to peptides. As predicted, TAPBPR revealed a hierarchy of exchangeability dependent on the intrinsic affinity of the MHC-I bound peptides. Additional studies revealed differences in the ability of distinct MHC-I allelomorphs to interact with and be catalyzed by TAPBPR (, 50). Dynamic studies of the exchange process using NMR revealed a negative allosteric function of TAPBPR (51). A practical outcome of the recognition of TAPBPR as a peptide editor has been its technological use in mediating peptide exchange, either with recombinant molecules (52) or at the cell surface (53).
The structural studies noted above generated new paradigms for understanding chaperone function in peptide loading. The X-ray structures, one of a complex of human TAPBPR with the murine H2-Db molecule (), the other of a complex of human TAPBPR with mouse H2-Dd () were remarkably similar. Comparison of the TAPBPR component of the two structures, determined independently in the two laboratories, revealed great similarity as indicated by a root-mean-square-deviation (RMSD) of superposed backbone carbon atoms of 0.935 Å. Figure 3 shows the TAPBPR/H2-Dd structure, showing how TAPBPR makes broad contact with the MHC-I molecule and its β2m light chain (Figures 3E, H). Contacts of MHC-I H and L chains to TAPBPR are also illustrated (Figures 3F, G). These X-ray structures were obtained by generating complexes between the TAPBPR and MHC-I molecules that had been either completely emptied by photolysis of a photolabile peptide (), or by engineering a disulfide linkage between the α1 helix of the MHC-I with a C-terminal cysteine substitution in the truncated 5-mer peptide (). Structures determined in the two laboratories revealed no consistent electron density in the binding groove, distortion of the empty binding groove by changes in the position of the α2-1 helix by at least 3 Å, and poor or non-existent electron density for a loop extending from residue 22 to 36 of TAPBPR. This loop, designated the scoop loop by some () clearly does not interact with the floor of the peptide binding groove at or near the F pocket which normally anchors the side chain of the C-terminal amino acid of the bound peptide. Some investigators have invoked a competitive function for this loop in TAPBPR (54), but others have argued that little evidence exists to substantiate such a model (51, 55). Indeed, NMR studies are consistent with the loop serving as a “peptide trap” by positioning itself above the MHC-I α1 and α2 helices (51). Another TAPBPR loop, extending from residues 209 to 213, interacts beneath the floor of the MHC-I peptide binding groove and plays a dynamic role in stabilizing peptide-free MHC-I molecules. In the structures determined by both laboratories, the disposition of a conserved tyrosine at position 84 of the MHC-I chain appears to play a role in either stabilizing bound peptide or in interacting with TAPBPR. The consistent feature of the TAPBPR structures was that they revealed extensive interactions of the membrane proximal IgC domain of TAPBPR with the membrane proximal Ig domains (α3 and β2m) of the MHC-I. Overall, X-ray crystallography studies of TAPBPR, complemented by detailed NMR studies (, 51, 56) and computational studies (57, 58) have contributed to a clearer picture of some of the details of the mechanism of peptide loading. Despite considerable interest and the valuable lessons of MHC-I chaperones learned from the study of TAPBPR, the precise function of TAPBPR remains somewhat of an enigma, since cells deficient in its expression reveal little effect on MHC-I surface expression.
Figure 3
2.3 Return to tapasin, the major MHC-I chaperone
The first cryo-EM structures of the complete PLC, though of relatively low resolution (), revealed the stoichiometry of the PLC to be consistent with that determined years earlier by antibody pull-down experiments that indicated a tapasin/MHC-I stoichiometry of either 2:1 or 2:2 in the PLC (59). These studies then set the stage for subsequent X-ray studies revealing the interactions of tapasin with MHC-I (, ). Efforts to produce complexes of tapasin with MHC-I molecules exploited various tricks to facilitate the interaction of the molecules that had been successful with TAPBPR (, ). Müller et al. took advantage of the stabilizing effect of ERp57 on tapasin and used the photolysis of bound peptide to generate multimeric complexes of human tapasin-Erp57 bound to the mouse H2-Db-human β2m heterodimer. They purified the higher order complexes and obtained X-ray quality crystals that diffracted to 2.7 Å resolution. Jiang et al. adapted an approach pioneered for MHC-II structural studies (60) and previously applied to TAPBPR in which carboxyl-terminally truncated peptides were disulfide linked to MHC-I molecules with a cysteine substitution in the α1 domain to permit refolding of molecules with partially empty peptide binding grooves. Binding studies of human tapasin to human HLA-B*44:05 revealed increased affinity for HLA-B molecules with partial occupancy of the peptide binding groove (), and, indeed, such a complex crystallized and yielded good diffraction data to 3.1 Å. In addition, structures of human tapasin bound independently with each of two different anti-tapasin monoclonal antibodies were reported (), and permitted modeling of the 11 to 20 loop of tapasin.
The general disposition of tapasin to the MHC-I in the two structures is largely the same as that of TAPBPR (see Figure 4), by which the concave surface of tapasin, like the similar surface of TAPBPR, nestles the MHC-I as a baseball glove holds a ball. Superposition of the tapasin moieties from the two structures reveals an RMSD of 3.15 Å, a considerable difference, due largely to differences in the disposition of the membrane proximal IgC domains of the two structures (compare Figure 4D with Figure 4K). This kind of domain flexibility is a common feature among multi-domain proteins. Whether some of the differences may be due to the potential stabilizing influence of the ERp57 in the trimolecular (MHC-I/tapasin/ERp57) complex requires further experimental test. Both structures reveal the influence of tapasin on the general conformation of the MHC-I peptide binding groove as compared with unliganded MHC-I. Again, as in the TAPBPR structures, no peptide ligand could be visualized in either of the tapasin/MHC complexes.
Figure 4
The loop of tapasin residues 11 to 20 is in roughly the same position as the longer comparable TAPBPR loop 22 to 36. Because of the lack of electron density of this loop, Jiang et al. examined this region in detail in the additional crystal structures of tapasin in complex with the monoclonal antibodies PaSta1 (61) and PaSta2 (, ). As predicted from their behavior in immunoprecipitation experiments, the antibodies bound at either a site competitive with the general region where MHC-I binds (PaSta2) or at a site on the opposite face of the molecule so that it can immunoprecipitate the complete MHC-I complex (PaSta1). Most importantly, in the tapasin-PaSta1 complex, the region of tapasin from Trp8 to Leu26 was in excellent electron density, permitting appropriate model building, revealing the loop to be perched above the MHC α-helices and distant from the floor of the F pocket. Again, for tapasin, as for TAPBPR, little convincing evidence supports a competitive model for the effects of this loop on peptide binding or release. Additional views of the tapasin 189-195 loop (analogous to residues 209-213 of TAPBPR) confirm the flexibility of this region. Comparison of the IgC domain of tapasin when bound to MHC-I or not, or of the α3 domain of MHC-I molecules either in complex with tapasin or not supports the view that interactions among the three membrane proximal domains—MHC-I α3, β2m, and IgC of tapasin—contribute dynamic interactions that stabilize a peptide-free state.
In the context of these structural studies, dynamics simulations have offered an additional perspective on the mechanisms by which tapasin contributes both to the stabilization of empty MHC-I molecules and the induction of peptide release from those complexed with low affinity peptides (62, 63). Understanding particular preferences of tapasin for a range of HLA types, occasionally those that differ even by a single amino acid polymorphism (64–66) provides further incentive for additional computational simulation and structural studies.
3 Summary and a view of the future
Tapasin-mediated peptide loading is a key step in the normal development of the immune system and for immune surveillance for neoplastic and infected cells. Deciphering nature’s solution to how a monomorphic chaperone such as tapasin engages many representatives of a polymorphic client poses a formidable challenge. The recently reported structures of tapasin-MHC-I complexes suggest that flexibility and dynamism of both tapasin and MHC-I are part of the answer. Here, we have summarized the current understanding that TAPBPR as well as tapasin in the PLC function by interacting dynamically and influence the structure of MHC molecules globally by contacting MHC-I across a broad interface with the MHC H chain and β2m resulting in MHC molecules that are either free of peptide or in a peptide-receptive state. As we enter into an era where experimental structural biology yields some of its insight to the triumphs of computational prediction (67–70), it is important to maintain the conviction that experimental observation forms the basis of our understanding of protein-protein interactions. Efforts to isolate functional components either experimentally or computationally, however, are fraught with the dangers of simplification of inherently complex systems. We must continue to explore new experimental approaches and we must remain receptive to and skeptical of models that almost always are based on insufficient data. Exploration of the complexities of immune recognition is only one of many scientific undertakings that offers at least partial solutions to autoimmunity, cancers, and newly evolving infectious agents.
Statements
Author contributions
DM, JJ, and KN outlined the original draft of this review. All authors participated in detailed discussion of the ideas and wrote different parts of the text. DM, JJ, JA, LB, and KN prepared and revised various Figures. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the intramural research program of the NIAID, NIH, under project numbers ZIA-AI000394 and ZIA-AI000622.
Acknowledgments
The authors thank colleagues who have shared reagents and ideas, and apologize in advance for inaccuracies or omissions in the referencing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
MarguliesDHNatarajanKRossjohnJMcCluskeyJ. The major histocompatibility complex. In: FlajnikMFSinghNJHollandSM, editors. Paul’s fundamental immunology, 8th ed. Philadelphia: Wolters Kluwer | Lippincott Williams & Wilkins (2023). p. 573–621.
2
BarkerDJMaccariGGeorgiouXCooperMAFlicekPRobinsonJet al. The IPD-IMGT/HLA database. Nucleic Acids Res (2023) 51(D1):D1053–D60. doi: 10.1093/nar/gkac1011
3
RobinsonJGuethleinLACerebNYangSYNormanPJMarshSGEet al. Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles. PloS Genet (2017) 13(6):e1006862. doi: 10.1371/journal.pgen.1006862
4
YewdellJWRochePAEisenlohrLC. Classical antigen processing and presentation. In: FlajnikMFSinghNJHollandSM, editors. Paul’s fundamental immunology, 8th ed. Philadelphia: Wolters Kluwer | Lippincott Williams & Wilkins (2023). p. 622–43.
5
RockKLReitsENeefjesJ. Present yourself! by MHC class I and MHC class II molecules. Trends Immunol (2016) 37(11):724–37. doi: 10.1016/j.it.2016.08.010
6
GermainRNMarguliesDH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol (1993) 11:403–50. doi: 10.1146/annurev.iy.11.040193.002155
7
BlumJSWearschPACresswellP. Pathways of antigen processing. Annu Rev Immunol (2013) 31:443–73. doi: 10.1146/annurev-immunol-032712-095910
8
JiangJNatarajanKBoydLFMorozovGIMageMGMarguliesDH. Crystal structure of a TAPBPR-MHC I complex reveals the mechanism of peptide editing in antigen presentation. Science (2017) 358(6366):1064–8. doi: 10.1126/science.aao5154
9
JiangJTaylorDKKimEJBoydLFAhmadJMageMGet al. Structural mechanism of tapasin-mediated MHC-I peptide loading in antigen presentation. Nat Commun (2022) 13(1):5470. doi: 10.1038/s41467-022-33153-8
10
ThomasCTampeR. Structure of the TAPBPR-MHC I complex defines the mechanism of peptide loading and editing. Science (2017) 358(6366):1060–4. doi: 10.1126/science.aao6001
11
MüllerIKWinterCThomasCSpaapenRMTrowitzschSTampeR. Structure of an MHC I-tapasin-ERp57 editing complex defines chaperone promiscuity. Nat Commun (2022) 13(1):5383. doi: 10.1038/s41467-022-32841-9
12
MorozovGIZhaoHMageMGBoydLFJiangJDolanMAet al. Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing. Proc Natl Acad Sci USA (2016) 113(8):E1006–15. doi: 10.1073/pnas.1519894113
13
BleesAJanulieneDHofmannTKollerNSchmidtCTrowitzschSet al. Structure of the human MHC-I peptide-loading complex. Nature (2017) 551(7681):525–8. doi: 10.1038/nature24627
14
DomnickAWinterCSusacLHenneckeLHensenMZitzmannNet al. Molecular basis of MHC I quality control in the peptide loading complex. Nat Commun (2022) 13(1):4701. doi: 10.1038/s41467-022-32384-z
15
FisetteOWingbermuhleSTampeRSchaferLV. Molecular mechanism of peptide editing in the tapasin-MHC I complex. Sci Rep (2016) 6:19085. doi: 10.1038/srep19085
16
SadasivanBLehnerPJOrtmannBSpiesTCresswellP. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity (1996) 5(2):103–14. doi: 10.1016/S1074-7613(00)80487-2
17
SadasivanBKCariappaAWaneckGLCresswellP. Assembly, peptide loading, and transport of MHC class I molecules in a calnexin-negative cell line. Cold Spring Harb Symp Quant Biol (1995) 60:267–75. doi: 10.1101/SQB.1995.060.01.031
18
DongGWearschPAPeaperDRCresswellPReinischKM. Insights into MHC class I peptide loading from the structure of the tapasin-ERp57 thiol oxidoreductase heterodimer. Immunity (2009) 30(1):21–32. doi: 10.1016/j.immuni.2008.10.018
19
TengMSStephensRDu PasquierLFreemanTLindquistJATrowsdaleJ. A human TAPBP (TAPASIN)-related gene, TAPBP-r. Eur J Immunol (2002) 32(4):1059–68. doi: 10.1002/1521-4141(200204)32:4<1059::AID-IMMU1059>3.0.CO;2-G
20
BoyleLHHermannCBonameJMPorterKMPatelPABurrMLet al. Tapasin-related protein TAPBPR is an additional component of the MHC class I presentation pathway. Proc Natl Acad Sci USA. (2013) 110(9):3465–70. doi: 10.1073/pnas.1222342110
21
McShanACNatarajanKKumirovVKFlores-SolisDJiangJBadstubnerMet al. Peptide exchange on MHC-I by TAPBPR is driven by a negative allostery release cycle. Nat Chem Biol (2018) 14(8):811–20. doi: 10.1038/s41589-018-0096-2
22
HermannCvan HaterenATrautweinNNeerincxADuriezPJStevanovicSet al. TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst. Elife (2015) 4. doi: 10.7554/eLife.09617
23
BermanHMBattistuzTBhatTNBluhmWFBournePEBurkhardtKet al. The protein data bank. Acta Crystallogr D Biol Crystallogr (2002) 58(Pt 6 No;1):899–907. doi: 10.1107/S0907444902003451
24
LawsonCLPatwardhanABakerMLHrycCGarciaESHudsonBPet al. EMDataBank unified data resource for 3DEM. Nucleic Acids Res (2016) 44(D1):D396–403. doi: 10.1093/nar/gkv1126
25
PettersenEFGoddardTDHuangCCMengECCouchGSCrollTIet al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci (2021) 30(1):70–82. doi: 10.1002/pro.3943
26
TruongHVSgourakisNG. Dynamics of MHC-I molecules in the antigen processing and presentation pathway. Curr Opin Immunol (2021) 70:122–8. doi: 10.1016/j.coi.2021.04.012
27
SiekerFSpringerSZachariasM. Comparative molecular dynamics analysis of tapasin-dependent and -independent MHC class I alleles. Protein Sci (2007) 16(2):299–308. doi: 10.1110/ps.062568407
28
SiekerFStraatsmaTPSpringerSZachariasM. Differential tapasin dependence of MHC class I molecules correlates with conformational changes upon peptide dissociation: a molecular dynamics simulation study. Mol Immunol (2008) 45(14):3714–22. doi: 10.1016/j.molimm.2008.06.009
29
KoopmannJOPostMNeefjesJJHammerlingGJMomburgF. Translocation of long peptides by transporters associated with antigen processing (TAP). Eur J Immunol (1996) 26(8):1720–8. doi: 10.1002/eji.1830260809
30
Van KaerLAshton-RickardtPGPloeghHLTonegawaS. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell (1992) 71(7):1205–14. doi: 10.1016/S0092-8674(05)80068-6
31
SaricTChangSCHattoriAYorkIAMarkantSRockKLet al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol (2002) 3(12):1169–76. doi: 10.1038/ni859
32
SaveanuLCarrollOLindoVDel ValMLopezDLepelletierYet al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol (2005) 6(7):689–97. doi: 10.1038/ni1208
33
SerwoldTGonzalezFKimJJacobRShastriN. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature (2002) 419(6906):480–3. doi: 10.1038/nature01074
34
LehnerPJSurmanMJCresswellP. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line.220. Immunity (1998) 8(2):221–31. doi: 10.1016/S1074-7613(00)80474-4
35
GarbiNTanPDiehlADChambersBJLjunggrenHGMomburgFet al. Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol (2000) 1(3):234–8. doi: 10.1038/79775
36
GrandeaAG3rdGolovinaTNHamiltonSESriramVSpiesTBrutkiewiczRRet al. Impaired assembly yet normal trafficking of MHC class I molecules in tapasin mutant mice. Immunity (2000) 13(2):213–22. doi: 10.1016/S1074-7613(00)00021-2
37
MorriceNAPowisSJ. A role for the thiol-dependent reductase ERp57 in the assembly of MHC class I molecules. Curr Biol (1998) 8(12):713–6. doi: 10.1016/S0960-9822(98)70279-9
38
ZachariasMSpringerS. Conformational flexibility of the MHC class I alpha1-alpha2 domain in peptide bound and free states: a molecular dynamics simulation study. Biophys J (2004) 87(4):2203–14. doi: 10.1529/biophysj.104.044743
39
WrightCAKozikPZachariasMSpringerS. Tapasin and other chaperones: models of the MHC class I loading complex. Biol Chem (2004) 385(9):763–78. doi: 10.1515/BC.2004.100
40
RizviSMRaghavanM. Direct peptide-regulatable interactions between MHC class I molecules and tapasin. Proc Natl Acad Sci USA (2006) 103(48):18220–5. doi: 10.1073/pnas.0605131103
41
ChenMStaffordWFDiedrichGKhanABouvierM. A characterization of the lumenal region of human tapasin reveals the presence of two structural domains. Biochemistry (2002) 41(49):14539–45. doi: 10.1021/bi020521u
42
ChenMBouvierM. Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection. EMBO J (2007) 26(6):1681–90. doi: 10.1038/sj.emboj.7601624
43
WearschPACresswellP. Selective loading of high-affinity peptides onto major histocompatibility complex class I molecules by the tapasin-ERp57 heterodimer. Nat Immunol (2007) 8(8):873–81. doi: 10.1038/ni1485
44
McShanACDevlinCAOverallSAParkJToorJSMoschidiDet al. Molecular determinants of chaperone interactions on MHC-I for folding and antigen repertoire selection. Proc Natl Acad Sci USA. (2019) 116(51):25602–13. doi: 10.1073/pnas.1915562116
45
OrtmannBCopemanJLehnerPJSadasivanBHerbergJAGrandeaAGet al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science (1997) 277(5330):1306–9. doi: 10.1126/science.277.5330.1306
46
GrandeaAG3rdLehnerPJCresswellPSpiesT. Regulation of MHC class I heterodimer stability and interaction with TAP by tapasin. Immunogenetics (1997) 46(6):477–83. doi: 10.1007/s002510050308
47
LiSSjogrenHOHellmanUPetterssonRFWangP. Cloning and functional characterization of a subunit of the transporter associated with antigen processing. Proc Natl Acad Sci USA. (1997) 94(16):8708–13. doi: 10.1073/pnas.94.16.8708
48
HermannCStrittmatterLMDeaneJEBoyleLH. The binding of TAPBPR and tapasin to MHC class I is mutually exclusive. J Immunol (2013) 191(11):5743–50. doi: 10.4049/jimmunol.1300929
49
NeerincxAHermannCAntrobusRvan HaterenACaoHTrautweinNet al. TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway. Elife (2017) 6. doi: 10.7554/eLife.23049
50
IlcaFTDrexhageLZBrewinGPeacockSBoyleLH. Distinct polymorphisms in HLA class I molecules govern their susceptibility to peptide editing by TAPBPR. Cell Rep (2019) 29(6):1621–32.e3. doi: 10.1016/j.celrep.2019.09.074
51
McShanACDevlinCAMorozovGIOverallSAMoschidiDAkellaNet al. TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap. Nat Commun (2021) 12(1):3174. doi: 10.1038/s41467-021-23225-6
52
OverallSAToorJSHaoSYarmarkovichMSaraMORMorozovGIet al. High throughput pMHC-I tetramer library production using chaperone-mediated peptide exchange. Nat Commun (2020) 11(1):1909. doi: 10.1038/s41467-020-15710-1
53
IlcaFTNeerincxAWillsMRde la RocheMBoyleLH. Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules. Proc Natl Acad Sci USA. (2018) 115(40):E9353–61. doi: 10.1073/pnas.1809465115
54
SagertLHennigFThomasCTampeR. A loop structure allows TAPBPR to exert its dual function as MHC I chaperone and peptide editor. Elife (2020) 9. doi: 10.7554/eLife.55326
55
MarguliesDHJiangJNatarajanK. Structural and dynamic studies of TAPBPR and tapasin reveal the mechanism of peptide loading of MHC-I molecules. Curr Opin Immunol (2020) 64:71–9. doi: 10.1016/j.coi.2020.04.004
56
McShanACDevlinCAPapadakiGFSunYGreenAIMorozovGIet al. TAPBPR employs a ligand-independent docking mechanism to chaperone MR1 molecules. Nat Chem Biol (2022) 18(8):859–68. doi: 10.1038/s41589-022-01049-9
57
van HaterenAElliottT. The role of MHC I protein dynamics in tapasin and TAPBPR-assisted immunopeptidome editing. Curr Opin Immunol (2021) 70:138–43. doi: 10.1016/j.coi.2021.06.016
58
XuHSongKDaLT. Dynamics of peptide loading into major histocompatibility complex class I molecules chaperoned by TAPBPR. Phys Chem Chem Phys (2022) 24(20):12397–409. doi: 10.1039/D2CP00423B
59
PanterMSJainALeonhardtRMHaTCresswellP. Dynamics of major histocompatibility complex class I association with the human peptide-loading complex. J Biol Chem (2012) 287(37):31172–84. doi: 10.1074/jbc.M112.387704
60
PosWSethiDKCallMJSchulzeMSAndersAKPyrdolJet al. Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell (2012) 151(7):1557–68. doi: 10.1016/j.cell.2012.11.025
61
DickTPBangiaNPeaperDRCresswellP. Disulfide bond isomerization and the assembly of MHC class I-peptide complexes. Immunity (2002) 16(1):87–98. doi: 10.1016/S1074-7613(02)00263-7
62
FleischmannGFisetteOThomasCWienekeRTumulkaFSchneeweissCet al. Mechanistic basis for epitope proofreading in the peptide-loading complex. J Immunol (2015) 195(9):4503–13. doi: 10.4049/jimmunol.1501515
63
LanHAbualrousETStichtJFernandezLMAWerkTWeiseCet al. Exchange catalysis by tapasin exploits conserved and allele-specific features of MHC-I molecules. Nat Commun (2021) 12(1):4236. doi: 10.1038/s41467-021-24401-4
64
PehCALahamNBurrowsSRZhuYMcCluskeyJ. Distinct functions of tapasin revealed by polymorphism in MHC class I peptide loading. J Immunol (2000) 164(1):292–9. doi: 10.4049/jimmunol.164.1.292
65
WilliamsAPPehCAPurcellAWMcCluskeyJElliottT. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity (2002) 16(4):509–20. doi: 10.1016/S1074-7613(02)00304-7
66
BashirovaAAViardMNaranbhaiVGrifoniAGarcia-BeltranWAkdagMet al. HLA tapasin independence: broader peptide repertoire and HIV control. Proc Natl Acad Sci USA. (2020) 117(45):28232–8. doi: 10.1073/pnas.2013554117
67
FershtAR. AlphaFold - a personal perspective on the imVpact of machine learning. J Mol Biol (2021) 433(20):167088. doi: 10.1016/j.jmb.2021.167088
68
JumperJEvansRPritzelAGreenTFigurnovMRonnebergerOet al. Highly accurate protein structure prediction with AlphaFold. Nature (2021) 596(7873):583–9. doi: 10.1038/s41586-021-03819-2
69
PerrakisASixmaTK. AI Revolutions in biology: the joys and perils of AlphaFold. EMBO Rep (2021) 22(11):e54046. doi: 10.15252/embr.202154046
70
TerwilligerTCPoonBKAfoninePVSchlicksupCJCrollTIMillanCet al. Improved AlphaFold modeling with implicit experimental information. Nat Methods (2022) 19(11):1376–82. doi: 10.1038/s41592-022-01645-6
Summary
Keywords
antigen presentation, tapasin, TAPBPR, MHC class I, peptide loading complex, structural immunology
Citation
Margulies DH, Jiang J, Ahmad J, Boyd LF and Natarajan K (2023) Chaperone function in antigen presentation by MHC class I molecules—tapasin in the PLC and TAPBPR beyond. Front. Immunol. 14:1179846. doi: 10.3389/fimmu.2023.1179846
Received
05 March 2023
Accepted
30 May 2023
Published
15 June 2023
Volume
14 - 2023
Edited by
Laura Mandik-Nayak, Lankenau Institute for Medical Research, United States
Reviewed by
Antony Nicodemus Antoniou, Northumbria University, United Kingdom; Scheherazade Sadegh-Nasseri, Johns Hopkins University, United States
Updates
Copyright
© 2023 Margulies, Jiang, Ahmad, Boyd and Natarajan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: David H. Margulies, dmargulies@niaid.nih.gov
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.